文献速递免疫规划传染病防控与疫情报告

德国成人社区获得性肺炎中肺炎球菌结合疫苗血清型分布及血清型3的主导作用

Pneumococcal conjugate serotype distribution and predominating role of serotype 3 in German adults with community-acquired pneumonia.
PubMed 文献 · Vaccine · 2019-11-21

研究在德国13价肺炎球菌结合疫苗(PCV13)婴儿免疫实施后3至7年间,前瞻性收集796例放射学确诊的成人社区获得性肺炎(CAP)患者尿标本,用血清型特异性多重尿抗原检测法(SSUAD)检测PCV13血清型。PCV13血清型见于7.4%的全病因CAP患者,以血清型3最常见(占59例中的50.8%);血清型3-CAP患者均住院,83.3%入院时需氧疗。2013至2016年PCV13血清型及血清型3比例未见时间趋势。

要点

  • PCV13血清型见于59/796(7.4%)全病因CAP成人患者,血清型3占59例中的50.8%。
  • 血清型3-CAP患者均住院,83.3%入院时需氧疗,高于其他血清型肺炎球菌CAP的50.9%(p=0.005)。
  • 常规微生物学检查漏检27/30(90.0%)血清型3-CAP病例。

核心结论

  • 常规方法低估可导致严重疾病的血清型3-CAP。
  • 2013至2016年未检测到PCV13总体覆盖率变化,主要由血清型3高比例驱动。

研究设计与样本

  • 多中心队列研究CAPNETZ于2012年12月至2017年1月前瞻性收集德国成人放射学确诊CAP患者尿标本,用SSUAD检测PCV13血清型。

主要发现

  • PCV13血清型见于59/796(7.4%)全病因CAP患者,血清型3占59例中的50.8%(30/59)。
  • 血清型3-CAP患者均住院,83.3%入院时需氧疗,其他血清型肺炎球菌CAP患者为50.9%(p=0.005)。
  • 常规微生物学检查漏检27/30(90.0%)血清型3-CAP病例。
  • 2013至2016年PCV13血清型比例无时间趋势(OR趋势每年0.84,95%CI 0.64-1.11),血清型3比例无时间趋势(OR趋势每年0.95,95%CI 0.70-1.28)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Implementation of the 7-valent pneumococcal conjugate vaccine (PCV7) in infant vaccination programs has substantially reduced the burden of PCV7 serotypes also in adult community-acquired pneumonia (CAP). Currently, it is unclear, if this extensive herd protection effect can be extrapolated to the additional 6 serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13), which replaced PCV7 in Germany in 2010. OBJECTIVES: We investigated changing trends for PCV13 serotypes in adult CAP patients between three to seven years after implementation of PCV13 infant immunization in Germany. METHODS: Between December 2012 and January 2017, urine samples from German adult patients with radiologically confirmed CAP were prospectively collected by the multi-center cohort study CAPNETZ and analyzed by the serotype-specific multiplex urinary antigen detection assay (SSUAD) allowing for the detection of PCV13 serotypes. RESULTS: PCV13 serotypes were found in 59 of 796 (7.4%) patients with all-cause CAP, most prevalent was serotype 3 (30 of 59 patients, 50.8%). All patients with serotype 3-CAP were admitted to hospital and the majority required oxygen at admission (83.3% of patients with serotype 3-CAP versus 50.9% of patients with pneumococcal CAP by other serotypes, p = 0.005). Compared to SSUAD testing, conventional microbiological workup missed 27 of 30 (90.0%) serotype 3-CAP cases. We could not observe a time trend in the proportions of PCV13 serotypes and serotype 3 in all-cause CAP between 2013 and 2016 (OR trend per year 0.84, 95% CI 0.64-1.11 for PCV13 serotypes and OR trend per year 0.95, 95% CI 0.70-1.28 for serotype 3). CONCLUSIONS: Conventional methods underestimate serotype 3-CAP that can cause severe disease. Changes in overall PCV13 coverage were not detected during the years 2013 to 2016, mostly driven by a high proportion of serotype 3.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Forstner C, Kolditz M, Kesselmeier M, et al. Pneumococcal conjugate serotype distribution and predominating role of serotype 3 in German adults with community-acquired pneumonia. Vaccine. 2019. PMID: 31761500. doi:10.1016/j.vaccine.2019.11.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。